Atacicept + Placebo matched to atacicept
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Optic Neuritis
Conditions
Optic Neuritis
Trial Timeline
Jun 1, 2008 → Jan 1, 2011
NCT ID
NCT00624468About Atacicept + Placebo matched to atacicept
Atacicept + Placebo matched to atacicept is a phase 2 stage product being developed by Merck for Optic Neuritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00624468. Target conditions include Optic Neuritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00624468 | Phase 2 | Terminated |
Competing Products
20 competing products in Optic Neuritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab 120 mg | Chugai Pharmaceutical | Approved | 85 |
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| Fingolimod 0.5mg/daily + Placebo | Novartis | Phase 2 | 52 |
| satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids | Roche | Phase 3 | 77 |
| Satralizumab | Roche | Phase 3 | 77 |
| UPLIZNA | Amgen | Pre-clinical | 22 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Approved | 84 |
| Zyvox - linezolid + Matched control | Pfizer | Phase 3 | 76 |
| Dexmedetomidine HCL Injection + Placebo | Pfizer | Phase 3 | 76 |
| No intervention | Pfizer | Pre-clinical | 22 |
| Efgartigimod Alfa + Placebo | Argenx | Phase 2 | 49 |
| Diagnostic procedures | Bayer | Approved | 82 |
| Placebo + BIIB033 100mg/Kg | Biogen | Phase 2 | 49 |
| BIIB033 (anti-LINGO-1 mAb) + Placebo | Biogen | Phase 2 | 49 |
| intravenous methylprednisolone | Brain Biotech | Pre-clinical | 15 |
| OCS-05 +SoC (corticosteroid) IV administration | Oculis Holding AG | Phase 2 | 47 |
| EVO756 + EVO756 + EVO756 + Placebo control | Evommune | Phase 2 | 47 |